EUVIMEDEUVIMED entdecken
Crossref

Discovery of Selective P2Y 6 R Antagonists with High Affinity and In Vivo Efficacy for Inflammatory Disease Therapy

Yifan Zhu, Mengze Zhou, Xiangyu Cheng, Hui Wang, Yehong Li, Yueyue Guo, Yaxuan Wang, Sheng Tian, Tianqi Mao, Zhoudong Zhang, Duxin Li iD, Qinghua Hu iD und 1 weitere

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Yifan Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, PR China. Hauptthemen laut MEDLINE: Colitis, Colitis, Ulcerative. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Suzhou Municipal Science and Technology Bureau, Qinglan Project of Jiangsu Province of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a member of purinoceptors, the P2Y6 receptor (P2Y6R) plays a crucial role in modulating immune signals and has been considered as a potential therapeutic target for inflammatory diseases. On the basis of the speculated probable conformation and binding determinants of P2Y6R, a hierarchical strategy that combines virtual screening, bioassays, and chemical optimization was presented. A potent P2Y6R antagonist (compound 50) was identified to possess excellent antagonistic activity (IC50 = 5.914 nM) and high selectivity. In addition, binding assays and chemical pull-down experiments confirmed that compound 50 was nicely bound to P2Y6R. Notably, compound 50 could effectively ameliorate DSS-induced ulcerative colitis in mice through inhibiting the activation of NLRP3 inflammasome in colon tissues. Moreover, treatment with compound 50 reduced LPS-induced pulmonary edema and infiltration of inflammatory cells in mice. These findings suggest that compound 50 could serve as a specific P2Y6R antagonist for treating inflammatory diseases and deserve further optimization studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisColitis, UlcerativeAnimalsMiceDextran SulfateInflammasomesMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinReceptors, Purinergic P2

Substanzen

Dextran SulfateInflammasomesNLR Family, Pyrin Domain-Containing 3 Proteinpurinoceptor P2Y6Receptors, Purinergic P2

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, PR China.
  • School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China.
  • Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215006, PR China.

ORCID-Profile: Duxin Li, Qinghua Hu, Huanqiu Li

Förderung

  • Suzhou Municipal Science and Technology Bureau
  • Qinglan Project of Jiangsu Province of China
  • Natural Science Foundation of Jiangsu Province
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • Natural science fund for colleges and universities in Jiangsu Province

Zitieren

APA

Zhu, Y., Zhou, M., Cheng, X., Wang, H., Li, Y., Guo, Y., Wang, Y., Tian, S., Mao, T., Zhang, Z., Li, D., Hu, Q., & Li, H. (2023). Discovery of Selective P2Y 6 R Antagonists with High Affinity and In Vivo Efficacy for Inflammatory Disease Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00210

Vancouver

Zhu Y, Zhou M, Cheng X, Wang H, Li Y, Guo Y, et al. Discovery of Selective P2Y 6 R Antagonists with High Affinity and In Vivo Efficacy for Inflammatory Disease Therapy. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00210

BibTeX
@article{Zhu2023,
  author = {Zhu, Yifan and Zhou, Mengze and Cheng, Xiangyu and Wang, Hui and Li, Yehong and Guo, Yueyue and Wang, Yaxuan and Tian, Sheng and Mao, Tianqi and Zhang, Zhoudong and Li, Duxin and Hu, Qinghua and Li, Huanqiu},
  title = {Discovery of Selective P2Y 6 R Antagonists with High Affinity and In Vivo Efficacy for Inflammatory Disease Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00210}
}
Kostenlos starten →